MediFind

Find a Doctor

Mark A. Ranalli

Nationwide Children's Hospital
Pediatrics, Hematology, Oncology
Male

Bio


Mark Ranalli is a Pediatrics specialist and a Hematologist in Columbus, Ohio. He has been an author on 21 peer reviewed articles and participated in 41 clinical trials in the past 15 years. Dr. Ranalli's top three areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Wilms Tumor. He is licensed to treat patients in OH.

Contact

700 Childrens Dr
Columbus, OH 43205, US

Latest Research


Latest Advance
Study
  • Condition: Young Cancer Patients
  • Journal: Molecular therapy : the journal of the American Society of Gene Therapy
  • Treatment Used: Intravenous Seprehvir
  • Number of Patients: 5
  • Published —
This study determined the safety of administering Seprehvir systemically, by conducting the first-in-human phase I trial of intravenous injection in young patients with relapsed or refractory extra-cranial solid cancers.

Clinical Trials


Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 70
  • Start Date: September 18, 2019
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 1220
  • Start Date: May 23, 2018
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 331
  • Start Date: October 10, 2017
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 24
  • Start Date: October 6, 2017
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 45
  • Start Date: October 2, 2017
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 144
  • Start Date: July 31, 2017
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 1500
  • Start Date: July 24, 2017
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 400
  • Start Date: June 5, 2017
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 256
  • Start Date: November 23, 2015
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 33000
  • Start Date: October 26, 2015
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 621
  • Start Date: July 28, 2014
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 65
  • Start Date: March 2014
A Phase II Study of <131>I-Metaiodobenzyguanidine (<131>I-MIBG) Therapy for Patients With MIBG Avid Tumors
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 1200
  • Start Date: September 15, 2008
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 4738
  • Start Date: May 19, 2008
Umbrella Long-Term Follow-Up Protocol
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 3885
  • Start Date: March 22, 2004
Key Adverse Events After Childhood Cancer
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 10000
  • Start Date: November 6, 2000
Neuroblastoma Biology Studies

All Publications
View All


Publication
Study
  • Journal: Pediatric blood & cancer
  • Published —
Cabozantinib for relapsed neuroblastoma: Single institution case series.
Publication
Study
  • Journal: Journal of pediatric hematology/oncology
  • Published —
Renal Tumors in Children and Young Adults Older Than 5 Years of Age.

Contact

700 Childrens Dr
Columbus, OH 43205, US

Credentials

  • Licenses
    Pediatric Hematology-Oncology in OH

Insurance

Contact them to find out if they accept your insurance plan.